Segment Information

12 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Segment Information

Segment Information

We operate as one operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, and, therefore, our chief operating decision-maker manages the operations of our company as a single operating segment. Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area and information relating to major customers are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.

Revenue by product is summarized as follows:

	For the Years Ended December 31,
	2015						2014						2013
(In millions)	United States		Rest of World		Total		United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
TECFIDERA	$	2,908.2	$	730.2	$	3,638.4	$	2,426.6	$	482.6	$	2,909.2	$	864.4	$	11.7	$	876.1
AVONEX	1,790.2		840.0		2,630.2		1,956.7		1,056.4		3,013.1		1,902.4		1,103.1		3,005.5
PLEGRIDY	227.1		111.4		338.5		27.8		16.7		44.5		—		—		—
TYSABRI	1,103.1		783.0		1,886.1		1,025.1		934.4		1,959.5		814.2		712.3		1,526.5
FAMPYRA	—		89.7		89.7		—		80.2		80.2		—		74.0		74.0
Hemophilia:
ELOCTATE	308.3		11.4		319.7		58.4		—		58.4		—		—		—
ALPROLIX	208.9		25.6		234.5		72.1		3.9		76.0		—		—		—
Other product revenues:
FUMADERM	—		51.4		51.4		—		62.5		62.5		—		60.2		60.2
Total product revenues	$	6,545.8	$	2,642.7	$	9,188.5	$	5,566.7	$	2,636.7	$	8,203.4	$	3,581.0	$	1,961.3	$	5,542.3

Geographic Information

The following tables contain certain financial information by geographic area:

December 31, 2015 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	6,545.8	$	1,497.6	$	668.1	$	143.7	$	333.3	$	9,188.5
Unconsolidated joint business revenues	$	1,269.8	$	3.5	$	—	$	—	$	65.9	$	1,339.2
Other revenues from external customers	$	142.0	$	29.6	$	1.6	$	62.9	$	—	$	236.1
Long-lived assets	$	1,296.5	$	879.4	$	2.3	$	7.7	$	1.7	$	2,187.6
December 31, 2014 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	5,566.7	$	1,383.9	$	811.8	$	112.8	$	328.2	$	8,203.4
Unconsolidated joint business revenues	$	1,117.1	$	7.7	$	—	$	—	$	70.6	$	1,195.4
Other revenues from external customers	$	212.6	$	31.6	$	1.8	$	58.5	$	—	$	304.5
Long-lived assets	$	1,055.5	$	701.9	$	2.5	$	2.6	$	3.2	$	1,765.7
December 31, 2013 (In millions)	U.S.		Europe(1)		Germany		Asia		Other		Total
Product revenues from external customers	$	3,581.0	$	1,170.2	$	417.7	$	93.2	$	280.2	$	5,542.3
Unconsolidated joint business revenues	$	1,087.3	$	1.6	$	—	$	3.2	$	33.9	$	1,126.0
Other revenues from external customers	$	193.5	$	26.1	$	1.2	$	43.1	$	—	$	263.9
Long-lived assets	$	984.4	$	758.3	$	2.5	$	2.1	$	3.3	$	1,750.7

(1) Represents amounts related to Europe less those attributable to Germany.

Revenues from Unconsolidated Joint Business

Approximately 12%, 12% and 16% of our total revenues in 2015, 2014 and 2013, respectively, are derived from our joint business arrangement with Genentech. For additional information related to our collaboration with Genentech, please read Note 19, Collaborative and Other Relationships to these consolidated financial statements.

Significant Customers

We recorded revenue from two wholesalers accounting for 34% and 26% of gross product revenues in 2015, 33% and 27% of gross product revenues in 2014, and 32% and 24% of gross product revenues in 2013, respectively.

Other

As of December 31, 2015, 2014 and 2013, approximately $684.9 million, $676.0 million and $731.1 million, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.